Vaccinex (VCNX) Competitors

$1.00 0.00 (0.00%)

As of 05/22/2026

VCNX vs. GRDX, APRE, KPRX, ZIVO, and IMNN

Should you buy Vaccinex stock or one of its competitors? MarketBeat compares Vaccinex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaccinex include Entero Therapeutics (GRDX), Aprea Therapeutics (APRE), Kiora Pharmaceuticals (KPRX), ZIVO Bioscience (ZIVO), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry.

How does Vaccinex compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Vaccinex (NASDAQ:VCNX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Vaccinex	Neutral

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Entero Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Entero Therapeutics has higher earnings, but lower revenue than Vaccinex. Entero Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	406.56	-$6.39M	-$1.69	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

Vaccinex's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-60.44%	-7.05%
Vaccinex	N/A	N/A	-383.58%

Summary

Entero Therapeutics and Vaccinex tied by winning 5 of the 10 factors compared between the two stocks.

How does Vaccinex compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Aprea Therapeutics currently has a consensus target price of $4.07, suggesting a potential upside of 328.07%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaccinex has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Vaccinex's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Vaccinex	N/A	N/A	-383.58%

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aprea Therapeutics has higher earnings, but lower revenue than Vaccinex. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	40.56	-$12.60M	-$1.54	N/A
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A

Aprea Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, Aprea Therapeutics' average media sentiment score of 1.00 beat Vaccinex's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Positive
Vaccinex	Neutral

Summary

Aprea Therapeutics beats Vaccinex on 9 of the 15 factors compared between the two stocks.

How does Vaccinex compare to Kiora Pharmaceuticals?

Vaccinex (NASDAQ:VCNX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Vaccinex's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 290.63%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, indicating that its share price is 148% less volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than Vaccinex. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Kiora Pharmaceuticals	Neutral

Summary

Kiora Pharmaceuticals beats Vaccinex on 8 of the 13 factors compared between the two stocks.

How does Vaccinex compare to ZIVO Bioscience?

Vaccinex (NASDAQ:VCNX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
ZIVO Bioscience	Neutral

Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ZIVO Bioscience has lower revenue, but higher earnings than Vaccinex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
ZIVO Bioscience	$15.85K	1,075.20	-$7.78M	-$1.71	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Vaccinex beats ZIVO Bioscience on 6 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Imunon?

Vaccinex (NASDAQ:VCNX) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Imunon had 8 more articles in the media than Vaccinex. MarketBeat recorded 8 mentions for Imunon and 0 mentions for Vaccinex. Imunon's average media sentiment score of 0.49 beat Vaccinex's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaccinex	Neutral
Imunon	Neutral

Imunon has lower revenue, but higher earnings than Vaccinex. Imunon is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.70	-$20.25M	-$48.27	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vaccinex's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Imunon	N/A	-341.23%	-153.79%

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Imunon has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Imunon has a consensus price target of $10.00, suggesting a potential upside of 354.55%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Imunon beats Vaccinex on 9 of the 14 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.60M	$797.21M	$6.39B	$12.31B
Dividend Yield	N/A	4.84%	2.76%	5.31%
P/E Ratio	-0.02	1.46	21.02	25.66
Price / Sales	6.70	124.41	557.65	83.76
Price / Cash	N/A	20.07	44.57	56.72
Price / Book	-0.39	7.59	10.37	7.14
Net Income	-$20.25M	-$3.91M	$3.56B	$335.72M
7 Day Performance	-9.09%	0.50%	5.10%	3.02%
1 Month Performance	-4.76%	80.42%	3.58%	2.88%
1 Year Performance	46.97%	123.37%	34.18%	35.20%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.00 flat	N/A	+47.0%	$2.60M	$388K	N/A	40	Upcoming Earnings
GRDX Entero Therapeutics	N/A	$3.45 +3.0%	N/A	N/A	$11.26M	$40K	N/A	9	Gap Down
APRE Aprea Therapeutics	4.2653 of 5 stars	$0.88 -2.2%	$4.40 +400.0%	-42.8%	$11.14M	$290K	N/A	7	News Coverage Positive News Gap Down
KPRX Kiora Pharmaceuticals	1.8913 of 5 stars	$2.69 +10.2%	$10.00 +271.7%	-16.6%	$10.81M	$16.02M	N/A	10
ZIVO ZIVO Bioscience	N/A	$2.70 -16.9%	N/A	-77.2%	$10.81M	$15.85K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 5/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. GRDX, APRE, KPRX, ZIVO, and IMNN

How does Vaccinex compare to Entero Therapeutics?

Summary

How does Vaccinex compare to Aprea Therapeutics?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Summary

How does Vaccinex compare to ZIVO Bioscience?

Summary

How does Vaccinex compare to Imunon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. GRDX, APRE, KPRX, ZIVO, and IMNN

How does Vaccinex compare to Entero Therapeutics?

Does the media favor GRDX or VCNX?

Do insiders & institutionals hold more shares of GRDX or VCNX?

Which has more volatility and risk, GRDX or VCNX?

Which has preferable valuation & earnings, GRDX or VCNX?

Is GRDX or VCNX more profitable?

Summary

How does Vaccinex compare to Aprea Therapeutics?

Do analysts prefer APRE or VCNX?

Is APRE or VCNX more profitable?

Do insiders & institutionals hold more shares of APRE or VCNX?

Which has better valuation and earnings, APRE or VCNX?

Which has more volatility and risk, APRE or VCNX?

Does the media favor APRE or VCNX?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Is VCNX or KPRX more profitable?

Do analysts prefer VCNX or KPRX?

Do institutionals and insiders believe in VCNX or KPRX?

Which has more risk & volatility, VCNX or KPRX?

Which has preferable valuation & earnings, VCNX or KPRX?

Does the media prefer VCNX or KPRX?

Summary

How does Vaccinex compare to ZIVO Bioscience?

Does the media refer more to VCNX or ZIVO?

Which has more volatility and risk, VCNX or ZIVO?

Do insiders and institutionals believe in VCNX or ZIVO?

Which has stronger valuation & earnings, VCNX or ZIVO?

Is VCNX or ZIVO more profitable?

Summary

How does Vaccinex compare to Imunon?

Does the media prefer VCNX or IMNN?

Which has preferable earnings & valuation, VCNX or IMNN?

Do institutionals & insiders hold more shares of VCNX or IMNN?

Is VCNX or IMNN more profitable?

Which has more volatility and risk, VCNX or IMNN?

Do analysts prefer VCNX or IMNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools